Blue Horseshoe Stocks: TRXC Recap & Much More

TransEnterix Inc. TRXC

TRXC stood out among the other mentions in Friday’s premarket report. Following our tag of this stock it shot quite rapidly from an early low of 2.73, and reached a subsequent high of 4.05 shortly after 11AM EST.

We want to congratulate any of our reader who were able to take advantage of that timely alert which yielded the opportunity at intraday gains of up to 48%  The healthy spike came on nearly tenfold the 3-month average trading volume.

Friday’s move came in conjunction with the announcement of successful pre-clinical trials for its SurgiBot minimally invasive surgery system. Two different doctors used TRXC’s product in actual medical procedures and subsequently offered their endorsements. It is an important step on the way to FDA application submission, which the company has stated should be on the table by mid-2015. Thus, TRXC may be one that we’ll want to have on a more long-term watch.

RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–TransEnterix, Inc. (NYSE MKT: TRXC), a medical device company that is pioneering the use of robotics and flexible instruments to improve minimally invasive surgery, today announced the successful completion of four general surgery and urology procedures using its SurgiBot system patient-side robotic surgery system. >> FULL PR

The First Marblehead Corp. FMD

We also wanted to give a quick nod to FMD for a solid performance following its inclusion in Friday morning’s watchlist. The stock found a low of 4.65 within the first several minutes of the open, and would go on to end the day with a on a high note, reaching as high as 5.35 and marking a respectable intraday move of 15%

Nuvilex, Inc. NVLX

Our first mention of NVLX dates all way back to August of 2013 when we released a special report on the company and its pancreatic cancer treatment, which at the time was in the early stages of Phase-2 trials. (Read the Special Report HERE)

A major development hit the presswires this morning regarding the FDA’s granting of ‘Orphan Drug’ status to that treatment, so we wanted to bring the stock back into the mix.

It’s coming off of a recent bottom as well, so NVLX is certainly going to be reserved a spot on our watchlist as the story continues to play out. The company has stated that Phase-3 trials should begin in 2015.

SILVER SPRING, Md., Dec. 22, 2014 (GLOBE NEWSWIRE) — Nuvilex, Inc. (NVLX), a clinical-stage biotechnology company providing cell therapy solutions for the treatment of diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Nuvilex orphan drug designation for its pancreatic cancer treatment. >> FULL PR

Rite-Aid Corp. RAD

We tagged RAD for tracking this past Tuesday, and the stock responded with a respectable performance on the week. An earnings beat as well as heightened guidance facilitated a healthy move from a low of 5.73 to a subsequent high of 7.05, marking a 23% intraweek spike.

Extended Watchlist:
GSS(Bottom Bouncer coming off 52-week lows), CANF, APP, TGE, ACHN

Blue Horseshoe Stocks: HUGE News in the Marijuana Industry

Medical/Legal Marijuana Sector Set to Explode

If that headline seems a little sensationalistic, that’s because something sensational has happened! Many of you will recall our continuous coverage of marijuana-related stocks beginning last year, as Washington and Colorado were getting ready to vote on becoming the first states to end more than seven decades of marijuana prohibition. The prospect of companies legally being able to cash in on what is most assuredly a multi-billion dollar industry just waiting to be unlocked, was and still is, quite exciting.

We rode several hemp stocks (which we’ll mention below) to astonishing gains, and have been continuously tracking the landscape of this burgeoning market sector ever since. Even with such progress being made in legislation, as well as a positive general shift in public opinion on the subject, we still had to temper our enthusiasm. The federal government had not yet taken an official position on the issue of whether or not it would intervene in the rights of individual states to grant their citizens access to legal marijuana. And so the nation, including several other states with legalization ambitions of their own, waited for news of their ultimate fate.

Then yesterday came… In the future, Thursday, August 29th, 2013, could very well be viewed as a turning point in the fight against marijuana prohibition. The US Department of Justice finally announced their official position: The federal government WILL NOT interfere with individual states who wish to legalize, regulate, and tax marijuana for both medical and personal recreational use. The door to a pot industry boom has just been unlocked, and left wide open.

In the wake of this historic event, we thought there would be no better time to remind our readers that this was one of the main reasons we’ve been so “high” on marijuana stocks for over a year now. It is rare to witness the birth of an entire industry, and yet it seems this baby has finally arrived! Check out the enormous list of related stocks below that have appeared in previous reports (I, II, III, IV) and be sure to keep them on your radars moving forward, as a world of possibilities (without fear of federal reprisal) has just opened up for the entire sector.


We’ll also be on the lookout for new marijuana related stocks, which are likely to start sprouting up like weeds now that the federal green light has been given. More on the subject is sure to come, so stay tuned to our daily reports, and good luck out there!

Incoming search terms:

  • erbb stock predictions

Blue Horseshoes Stocks: Afternoon Update

Nuvilex, Inc. NVLX

NVLX, after starting off the day as low as .125, is testing new highs this afternoon, having just touched a high of .1425 for a 14% intraday increase.

A quick look at the chart shows the stock broke above the 50DMA, a good sign, and the RSI is trying to  get back above the 50-line. We’re also on the lookout for a bullish MACD cross, as we pointed out in the NVLX video chart,which was featured in yesterday’s NVLX Special Report.


IWEB opened as low as .0324 this morning, and managed a high of .038 (+17%). We then saw a dip back to .034, and currently it’s trading back at the .0355 level. So all in all, we seen some nice price action from IWEB today, including those intraday moves which amount the possibility of up to 21% in cumulative gains on the day.

In total, IWEB has brought us the opportunity at well over 300% in gains since we initiated coverage back on July 9th.

We’ll also add that the BARCHART.COM Opinion on IWEB still reads green, to the tune of a 72% Overall “Buy” Rating.

NVLX | Nuvilex, Inc. | Today’s Focus

We’re adding a new play to our watchlists this morning: Nuvilex, Inc. (NVLX) is a multi-faceted biotech company that has been extremely active in the growth and development of its business over the past month.

NVLX has launched itself into the biotechnology industry with the recently completed full acquisition of Bio Blue Bird AG, which has a proprietary live-cell encapsulation technology which acts as a delivery system for live cells that aid in the treatment of inoperable pancreatic cancer and breast cancer, as well as diabetes.

In fact the technology as a whole can be viewed simply as a platform upon which virtually limitless treatments could be built. Opportunities abound, not only with the follow-though of its own products, but at the prospect of other companies lining up to license NVLX‘s encapsulation technology for use in delivering their own treatments.

The cellulose-based capsules really are a work of genius. At the scale of a pin-head, the microscopic capsules are filled with living cells, either engineered or cultured from natural compounds that are believed to have therapeutic effects, and introduced into the body intravenously or through direct injection. They contain pores which are too small in size to allow for the escape of the cells (or access to immune system cells that might try to destroy the introduced cells), but sufficient in size to facilitate the entry of essential nutrients exit of and waste products and beneficial substances produced by the cells. In this state, the encapsulated samples can survive for long periods of time.

The FDA recently rolled out a new program in which certain approved technologies can receive a  “breakthrough therapy” designation. This designation aids the FDA in helping firms speed up the development of new drugs or therapies that have shown sufficient potential to offer statistically significant improvement over existing treatments for terminal illnesses. If Nuvilex could get approved for this new fast-track program, shares which are now trading in the teens, could soon see much higher value. That’s much of the reason that we’re so excited about the possibilities for NVLX. We think promising Phase II results that have been reported by Nuvilex could lead to Phase III trials under this new program, which would mean big things for this biotech.

For instance, below you can see an image taken from Nuvilex’s website which shows before and after scans of what can only be described as extremely encouraging apparent success in treating a pancreatic tumor.

With one stroke, Nuvilex has catapulted itself into the midst of an exciting prospect- A proprietary, license-able technology that could not only have far reaching implications in business, but how terminal illnesses of all kinds can be treated; something that could benefit all mankind. If it sounds like it has the potential to be a really big deal, that’s because it does. The fact that we’ve stumbled upon this company at this early stage of its new evolution could have some pretty impressive effects as well with regard to the stock.

The addition of this potentially game-changing tech goes well with another arm of NVLX‘s business, Medical Marijuana Sciences, Inc, which is focused on the use of marijuana and its various chemical compounds for the development of treatment for different types of cancer. As many of our followers are well aware, the medical marijuana industry is one that has been of great interest and profit to us over the past year.

Have a look at the NVLX chart below, or click through to the video chart presentation:


Recent PRs

>>View All Recent Press

For More Information visit

Blue Horseshoe Stocks: LATF, Midday Updates

Latteno Food Corp. LATF

Most of our regular readers will remember us talking about LATF, along with all of the other medical and legal marijuana-related stocks that we have been tracking recently. We mentioned LATF specifically, as recently as March 26th. We talked about how we had brought it to our readers at the beginning of February, as low as .023, only to see it run to .23, gaining as much as 900% in the process.

We had been observing as it began to cool down, mentioning that we were on the lookout for a bottom, and another chance to take LATF for a ride. It reached that bottom the very next day, on the 27th, touching .015 before beginning the recovery that we were after. The stock has continued this recovery through last week and into this week, and today, has reached as high as .044. That represents a highly respectable 193% move in a span of just two weeks.


Like we stated above, LATF is just one of cannabis related stocks that we have been tracking this year, as our regular readers will remember, we have canvassed the sector for quite some time, and it has been one of our favorite and most lucrative areas of interest recently. To the already sizable list of marijuana plays, we have several related additions for you this afternoon, that we feel should be added to our running watchlist. We suggest our readers keep similar watchlists of their own.

AERO – Aero Grow International, Inc.
AQNM – Aquentium, Inc.
ATTBF – Abattis Bioceuticals Corp
AVTC – AVT, Inc.
BISU – Bio-Solutions Corp.
CANV – CannaVest Corp.
CIIX –, Inc.
CTH.V – Cynapsus Therapeutics Inc.
ECUI – Ecuity, Inc. -
GTLA – GT Legend Automotive Holdings Inc.
GWPH – GW Pharmaceuticals Plc.
GWPRF – GW Pharmaceuticals Plc.
HESG – Health Sciences Group, Inc.
NRBT – Novus Robotics, Inc.
NTRR – Neutra Corp.
NVLX – Nuvilex, Inc.
PARS – Pharmos Corp.
SRER – SearchCore, Inc.
STBV – Strategic Global Investments, Inc.